Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

NCT: NCT02997553 · COMPLETED

NCT IDNCT02997553
StatusCOMPLETED
Start Date2017-11-29
Completion2022-10-12
SponsorInstitut de Cancérologie de Lorraine (OTHER)
First posted
Last updated

Brief Summary

This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with cancers and subjected to surgery. The diagnostic performance and the tolerance of indocyanine green (ICG) to the radio-isotope (Techniciun99) in the detection of sentinel lymph nodes will be assess using an "Optonuclear" probe (EURORAD S.A.) and QUEST camera

Frequently Asked Questions

What is Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery?

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery is a clinical trial registered under NCT02997553. Current status: COMPLETED.

What is the status of NCT02997553?

The current status of NCT02997553 (Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery) is: COMPLETED.

When did Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery start?

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery started on 2017-11-29.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.